Innovita Biological Technology Co. Ltd. A Market Cap ($1.00 Billion)
Market Cap & Net Worth: Innovita Biological Technology Co. Ltd. A (688253)
Innovita Biological Technology Co. Ltd. A market cap. Innovita Biological Technology Co. Ltd. A (SHG:688253) has a market capitalization of $1.00 Billion (CN¥6.85 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #8580 globally and #2002 in its home market, demonstrating a 4.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innovita Biological Technology Co. Ltd. A's stock price CN¥49.97 by its total outstanding shares 136984316 (136.98 Million). Also see Innovita Biological Technology Co. Ltd. (688253) cash conversion ratio for how efficiently the company converts equity into cash flow.
Innovita Biological Technology Co. Ltd. A Market Cap History (2022–2026)
Innovita Biological Technology Co. Ltd. A market cap history from 2022 to 2026. Data shows growth from $469.52 Million to $1.00 Billion (10.61% CAGR). Check Innovita Biological Technology Co. Ltd. share price for real-time trading data and today's change.
Innovita Biological Technology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innovita Biological Technology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 688253 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.43x
Innovita Biological Technology Co. Ltd. A's market cap is 1.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.19x
Innovita Biological Technology Co. Ltd. A's market cap is 4.19 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $469.52 Million | $446.62 Million | $150.68 Million | 1.05x | 3.12x |
| 2023 | $496.29 Million | $478.02 Million | $173.95 Million | 1.04x | 2.85x |
| 2024 | $726.84 Million | $621.39 Million | $246.86 Million | 1.17x | 2.94x |
| 2025 | $604.96 Million | $422.03 Million | $144.47 Million | 1.43x | 4.19x |
Competitor Companies of 688253 by Market Capitalization
Companies near Innovita Biological Technology Co. Ltd. A in the global market cap rankings as of November 8, 2026. Also see 688253 total assets for a full breakdown of the balance sheet.
Key companies related to Innovita Biological Technology Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Innovita Biological Technology Co. Ltd. A (2022–2026)
Market capitalization of Innovita Biological Technology Co. Ltd. A from 2022 to today. Between 2022 and today, Innovita Biological Technology Co. Ltd. A's market cap moved from $469.52 Million to $ 1.00 Billion, with a yearly change of 10.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.00 Billion | +65.57% |
| 2025 | CN¥604.96 Million | -16.77% |
| 2024 | CN¥726.84 Million | +46.45% |
| 2023 | CN¥496.29 Million | +5.70% |
| 2022 | CN¥469.52 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Innovita Biological Technology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.00 Billion USD |
| MoneyControl | $1.00 Billion USD |
| MarketWatch | $1.00 Billion USD |
| marketcap.company | $1.00 Billion USD |
| Reuters | $1.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.